Enalapril patient counseling information: Difference between revisions
Amr Marawan (talk | contribs) (Created page with "__NOTOC__ {{Enalapril}} {{CMG}}; {{AE}} {{AM}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENAL...") |
Amr Marawan (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AM}} | {{CMG}}; {{AE}} {{AM}} | ||
==Information for Patients== | |||
====Angioedema==== | |||
[[Angioedema]], including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref> | ====Hypotension==== | ||
Patients should be cautioned to report [[lightheadedness]], especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. | |||
All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. | |||
====Hyperkalemia==== | |||
Patients should be told not to use salt substitutes containing potassium without consulting their physician. | |||
====Neutropenia==== | |||
Patients should be told to report promptly any indication of infection (e.g., [[sore throat]], [[fever]]) which may be a sign of [[neutropenia]]. | |||
====Pregnancy==== | |||
Female patients of childbearing age should be told about the consequences of exposure to [[ACE inhibitors]]. These patients should be asked to report pregnancies to their physicians as soon as possible. | |||
NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 21:23, 12 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Enalapril
Enalapril and Hydrochlorothiazide
Enalapril and Felodipine
Overview
Enalapril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]
Information for Patients
Angioedema
Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.
Hypotension
Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.
All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.
Hyperkalemia
Patients should be told not to use salt substitutes containing potassium without consulting their physician.
Neutropenia
Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.
Pregnancy
Female patients of childbearing age should be told about the consequences of exposure to ACE inhibitors. These patients should be asked to report pregnancies to their physicians as soon as possible.
NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.[1]
References
Adapted from the FDA Package Insert.